Skip to main content

Embolism

2
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
CertoparinPhase 31 trial
Active Trials
NCT00311753Completed342
Emboline
EmbolineCA - Santa Cruz
1 program
1
Emboliner Embolic ProtectionPhase 21 trial
Active Trials
NCT05684146Unknown540Est. Dec 2024
Novartis
NovartisBASEL, Switzerland
1 program
CertoparinPHASE_3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozCertoparin
EmbolineEmboliner Embolic Protection

Clinical Trials (2)

Total enrollment: 882 patients across 2 trials

Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients

Start: Feb 2006342 patients
Phase 3Completed
NCT05684146EmbolineEmboliner Embolic Protection

Protect the Head to Head Study

Start: May 2023Est. completion: Dec 2024540 patients
Phase 2Unknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.